[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353991-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353991-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-kif23-inhibits-cell-proliferation-and-primary-chemoresistance-in-cervical-cancer-by-inactivating-the-myh9mcm2pcna-pathway","Targeting KIF23 inhibits cell proliferation and primary chemoresistance in cervical cancer by inactivating the MYH9/MCM2/PCNA pathway","","Kinesin family member 23 (KIF23) is investigated as a tumour promoter in cervical cancer, focusing on how it drives tumour growth and primary chemoresistance. Expression and prognostic value are first evaluated via bioinformatic analyses and then confirmed in clinical specimens. Functional effects on proliferation and cisplatin sensitivity are tested using CRISPR/Cas9 knockout, overexpression, and mouse xenograft models, with mechanistic support from co-immunoprecipitation, ubiquitination, and protein half-life assays. Results indicate that KIF23 suppression blocks proliferation, induces G1 arrest, and sensitises cells to cisplatin through the MYH9/MCM2/PCNA axis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-kif23-inhibits-cell-proliferation-and-primary-chemoresistance-in-cervical-cancer-by-inactivating-the-myh9mcm2pcna-pathway/353991/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-kif23-inhibits-cell-proliferation-and-primary-chemoresistance-in-cervical-cancer-by-inactivating-the-myh9mcm2pcna-pathway/353991.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is KIF23’s role in cervical cancer progression?","Question",{"text":63,"@type":64},"KIF23 is recognised as an important tumour promoter in cervical cancer and its expression correlates with poor prognosis and cisplatin resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did researchers test the effects of KIF23 on cisplatin sensitivity?",{"text":68,"@type":64},"They used CRISPR/Cas9 knockout and overexpression in cell models and evaluated cisplatin response in vitro and in vivo using mouse xenograft models.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism links KIF23 to the MYH9/MCM2/PCNA pathway?",{"text":72,"@type":64},"The C-terminal domain of KIF23 binds to MYH9, recruiting USP7 to remove K48-linked ubiquitination of MYH9, stabilising it and enabling downstream regulation involving USP15, MCM2 and PCNA.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353991,1790176540,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DOI: 10.1002/ctm2.70652  \nRESEARCH ARTICLE  \nTargeting KIF23 inhibits cell proliferation and primary chemoresistance in cervical cancer by inactivating the MYH9/MCM2/PCNA pathway  \nYing Zhu1 Zike Yang3  \nQian Wang1  Yilin Zhang1  Yahui Liu2  Xiaojie Deng4   Suiqun Guo1   \nHaini Fu1  \n1 Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China  \n2 School of Basic Medical Sciences, Guangdong Medical University, Dongguan, China  \n3 Department of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China  \n4 Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China  \nCorrespondence  \nZike Yang, Department of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. [Email:](Email: yangzike@xmu.edu.cn)[ yangzike@xmu.edu.cn](Email: yangzike@xmu.edu.cn)  \nXiaojie Deng, Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.  \nEmail: [sophiexiaojie@qq.com](sophiexiaojie@qq.com)  \nSuiqun Guo, Department of Obstetricsand Gynecology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.  \n[Email:](Email: guosq2005@126.com)[ guosq2005@126.com](Email: guosq2005@126.com)  \nGraphical Abstract  \n∙ Cisplatin treatment induces KIF23 expression in a concentration- and timedependent manner.  \n∙ KIF23 recruits USP7, which removes the K48-linked ubiquitin chain of MYH9, thereby stabilising MYH9 and facilitating its nuclear transport.  \n∙ MYH9 recruits USP15, thereby stabilising MCM2, which, in turn, regulates the G1/S phase transition by binding to PCNA.  \n∙ Targeting the KIF23/MYH9/MCM2/PCNA axis sensitises cervical cancer cells to cisplatin.  \nClin. Transl. Med. 2026;16:e70652 .  \n[https://doi.org/10.1002/ctm2.70652](https://doi.org/10.1002/ctm2.70652)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nDOI: 10.1002/ctm2.70652  \nRESEARCH ARTICLE  \nTargeting KIF23 inhibits cell proliferation and primary chemoresistance in cervical cancer by inactivating the MYH9/MCM2/PCNA pathway  \nYing Zhu1 Zike Yang3  \nQian Wang1  Yilin Zhang1  Yahui Liu2  Xiaojie Deng4   Suiqun Guo1   \nHaini Fu1  \n1 Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China  \n2 School of Basic Medical Sciences, Guangdong Medical University, Dongguan, China  \n3 Department of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China  \n4 Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China  \nCorrespondence  \nZike Yang, Department of Oncology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. [Email:](Email: yangzike@xmu.edu.cn)[ yangzike@xmu.edu.cn](Email: yangzike@xmu.edu.cn)  \nXiaojie Deng, Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.  \nEmail: [sophiexiaojie@qq.com](sophiexiaojie@qq.com)  \nSuiqun Guo, Department of Obstetricsand Gynecology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. [Email:](Email: guosq2005@126.com)[ guosq2005@126.com](Email: guosq2005@126.com)  \nFunding information  \nYoung and Middle-Aged Backbone Talents Cultivation Program for  \nHigh-Quality Health Development, Xiamen Municipal Health Commission, Grant/Award Number: 2024GZL-GG46  \nAbstract  \nBackground: Kinesin family member 23 (KIF23) is recognised as an important tumour promoter involved in the pathogenesis of various cancers. However, its role and underlying molecular mechanisms in regulating cervical cancer (CC) growth and primary chemoresistance remain to be fully elucidated.  \nMethods: The expression and p","cbCainagZjpyDl8K","https://ap.wps.com/l/cbCainagZjpyDl8K","pdf",13948779,21,"English","# Abstract\n## Background\n## Methods\n## Results","[{\"question\":\"What is KIF23’s role in cervical cancer progression?\",\"answer\":\"KIF23 is recognised as an important tumour promoter in cervical cancer and its expression correlates with poor prognosis and cisplatin resistance.\"},{\"question\":\"How did researchers test the effects of KIF23 on cisplatin sensitivity?\",\"answer\":\"They used CRISPR/Cas9 knockout and overexpression in cell models and evaluated cisplatin response in vitro and in vivo using mouse xenograft models.\"},{\"question\":\"What mechanism links KIF23 to the MYH9/MCM2/PCNA pathway?\",\"answer\":\"The C-terminal domain of KIF23 binds to MYH9, recruiting USP7 to remove K48-linked ubiquitination of MYH9, stabilising it and enabling downstream regulation involving USP15, MCM2 and PCNA.\"}]","Targeting KIF23 inhibits cell proliferation and primary chemoresistance in cervical cancer by inactivating the MYH9/MCM2/PCNA pathway | PDF",1790108375,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97e4cd909d09bddab854c1e1b542bc52.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dce8884722aec932f0304b96acd6623f.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8209379ad881d3df34fc76bee80493ad.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6902f88ad8c00f3c86979b6e62e8ee33.webp",980,1287]